These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 29999301)

  • 41. Effect of a heparan sulphate with high affinity for antithrombin III upon inactivation of thrombin and coagulation factor Xa.
    Scully MF; Ellis V; Shah N; Kakkar V
    Biochem J; 1989 Sep; 262(2):651-8. PubMed ID: 2529852
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Activated Factor X-Based versus Thrombin-Based Antithrombin Testing in Thrombophilia Workup in the DOAC Era.
    Rühl H; Reda S; Müller J; Oldenburg J; Pötzsch B
    Thromb Haemost; 2018 Feb; 118(2):381-387. PubMed ID: 29378360
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Control of contact activation on end-point immobilized heparin: the role of antithrombin and the specific antithrombin-binding sequence.
    Sanchez J; Elgue G; Riesenfeld J; Olsson P
    J Biomed Mater Res; 1995 May; 29(5):655-61. PubMed ID: 7622551
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The role of Arg46 and Arg47 of antithrombin in heparin binding.
    Arocas V; Bock SC; Olson ST; Björk I
    Biochemistry; 1999 Aug; 38(31):10196-204. PubMed ID: 10433728
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Antithrombin binding of low molecular weight heparins and inhibition of factor Xa.
    Lin P; Sinha U; Betz A
    Biochim Biophys Acta; 2001 Apr; 1526(1):105-13. PubMed ID: 11287128
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Determinants of specificity of factor xa interaction with its physiological inhibitors.
    Rezaie AR
    Mini Rev Med Chem; 2006 Aug; 6(8):859-65. PubMed ID: 16918492
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effect of SanOrg123781A, a synthetic hexadecasaccharide, on clot-bound thrombin and factor Xa in vitro and in vivo.
    Hérault JP; Cappelle M; Bernat A; Millet L; Bono F; Schaeffer P; Herbert JM
    J Thromb Haemost; 2003 Sep; 1(9):1959-65. PubMed ID: 12941037
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Heparin and low molecular weight heparins as scaffolds for assembling antithrombin and serine proteases.
    Ofosu FA
    Thromb Res; 2008; 123(1):5-7. PubMed ID: 18284938
    [No Abstract]   [Full Text] [Related]  

  • 49. Monitoring high-dose heparinization during cardiopulmonary by-pass--a comparison between prothrombinase-induced clotting time (PiCT) and two chromogenic anti-factor Xa activity assays.
    Raivio P; Kuitunen A; Petäjä J; Ilveskero S; Lassila R
    Thromb Haemost; 2008 Feb; 99(2):427-34. PubMed ID: 18278195
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Covalent antithrombin-heparin complexes.
    Patel S; Berry LR; Chan AK
    Thromb Res; 2007; 120(2):151-60. PubMed ID: 16978685
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Experimental proof for the structure of a thrombin-inhibiting heparin molecule.
    Petitou M; Imberty A; Duchaussoy P; Driguez PA; Ceccato ML; Gourvenec F; Sizun P; Hérault JP; Pérez S; Herbert JM
    Chemistry; 2001; 7(4):858-73. PubMed ID: 11288878
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Interaction of factor Xa with heparin does not contribute to the inhibition of factor Xa by antithrombin III-heparin.
    Owen BA; Owen WG
    Biochemistry; 1990 Oct; 29(40):9412-7. PubMed ID: 2248954
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The influence of acetaldehyde and glycosaminoglycans upon factor Xa- and factor X-deficient plasma.
    Brecher AS; Hommema EL
    Can J Physiol Pharmacol; 2002 Sep; 80(9):879-86. PubMed ID: 12430983
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Serpin-independent anticoagulant activity of a fucosylated chondroitin sulfate.
    Glauser BF; Pereira MS; Monteiro RQ; Mourão PA
    Thromb Haemost; 2008 Sep; 100(3):420-8. PubMed ID: 18766257
    [TBL] [Abstract][Full Text] [Related]  

  • 55. High-performance liquid chromatographic/mass spectrometric studies on the susceptibility of heparin species to cleavage by heparanase.
    Bisio A; Mantegazza A; Urso E; Naggi A; Torri G; Viskov C; Casu B
    Semin Thromb Hemost; 2007 Jul; 33(5):488-95. PubMed ID: 17629845
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Protection of factor Xa from neutralization by the heparin-antithrombin complex.
    Teitel JM; Rosenberg RD
    J Clin Invest; 1983 May; 71(5):1383-91. PubMed ID: 6222069
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Defining the heparin-binding domain of antithrombin.
    Wu YI; Sheffield WP; Blajchman MA
    Blood Coagul Fibrinolysis; 1994 Feb; 5(1):83-95. PubMed ID: 8180343
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Edoxaban, a direct factor Xa inhibitor, suppresses tissue-factor induced human platelet aggregation and clot-bound factor Xa in vitro: Comparison with an antithrombin-dependent factor Xa inhibitor, fondaparinux.
    Honda Y; Kamisato C; Morishima Y
    Thromb Res; 2016 May; 141():17-21. PubMed ID: 26962981
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Measurement of antithrombin activity by thrombin-based and by factor Xa-based chromogenic substrate assays.
    Beeck H; Nagel D; Pindur G; Scharrer I; Preiss A; Seiler D; Hellstern P
    Blood Coagul Fibrinolysis; 2000 Mar; 11(2):127-35. PubMed ID: 10759005
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effects of heparin fractions of different affinities to antithrombin III and thrombin on the inactivation of thrombin and factor Xa by antithrombin III.
    Cerskus AL; Birchall KJ; Ofosu FA; Hirsh J; Blajchman MA
    Can J Biochem Cell Biol; 1984 Oct; 62(10):975-83. PubMed ID: 6509363
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.